Growth Hormone, Cardiovascular Risk, and Visceral Adiposity
Status:
Completed
Trial end date:
2013-06-01
Target enrollment:
Participant gender:
Summary
This study will compare growth hormone levels and cardiovascular risk markers in normal
weight and overweight women and men. In women and men with increased abdominal weight, growth
hormone (GH) versus placebo will be administered and effects on cardiovascular risk, insulin
resistance and body composition will be measured.